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Paper commissioned and endorsed by (in alphabetical order) Spanish Societies of Anaesthesiology and Reanimation 
(SEDAR), Critical Care Medicine (SEMICYUC), Haematology and Haemotherapy (SEHH), Hospital Pharmacy 
(SEFH), Thrombosis and Haemostasis (SETH), and Transfusion and Cellular Therapy (SETS)
Summary of recommendations on alternatives 
to reduce allogeneic blood transfusion (in 
descending order of strength)
Grade 1A recommendations
We recommend:
- The use of restrictive transfusion strategies in non-
bleeding, euvolaemic anaemic patients.
- Perioperative administration of tranexamic acid to 
patients undergoing cardiac surgery.
- The administration of intravenous iron to cancer 
patients, as an adjuvant to erythropoiesis-stimulating 
agents, for correcting chemotherapy-induced anaemia.
- Preoperative administration of erythropoiesis-
stimulating agents to anaemic, orthopaedic surgical 
patients expected to have moderate blood losses. 
We do not recommend:
- The administration of desmopressin to patients 
undergoing elective surgery.
- The administration of erythropoiesis-stimulating 
agents to critically ill patients who do not have a 
previous indication for this therapy.
Grade 1B recommendations
We recommend: 
- Perioperative cell salvage in patients undergoing 
surgery for total hip or knee arthroplasty, cardiac 
procedures with cardiopulmonary bypass, or 
abdominal aorta aneurysm repair.  
- Perioperative administration of epsilon-aminocaproic 
acid to patients undergoing cardiac surgery. 
- Perioperative administration of tranexamic acid to 
patients undergoing hepatic surgery or bleeding trauma.
- The administration of intravenous iron to patients 
with post-partum anaemia or inflammatory bowel 
disease associated anaemia.
We do not recommend:
- Preoperative autologous blood donation in surgical 
procedures generally requiring the transfusion of two 
or fewer units of packed red cells.
- Routine use of acute normovolaemic haemodilution, 
as the single blood-sparing technique, in major surgery.
- Perioperative administration of epsilon-aminocaproic 
acid in orthopaedic surgical procedures.
- The administration of oral iron in the postoperative 
period or in critically ill patients.
Grade 1C recommendations
We recommend:
- Preoperative autologous blood donation in 
orthopaedic surgical procedures generally requiring 
the transfusion of three or more units of packed red 
cells.
- Perioperative cell salvage in complex spinal surgery, 
in combination with other blood-saving strategies.
- The use of thromboelastography in surgical or trauma 
patients presenting with severe bleeding.
- The administration of prothrombin complex 
concentrates to patients treated with vitamin 
K antagonists and presenting with intracranial 
haemorrhage.
- Thromboelastography-guided administration of 
fibrinogen concentrates to surgical or trauma patients 
presenting with severe bleeding.
- Fluid resuscitation in patients with mild to moderate 
blood losses.
Grade 2A recommendations
We suggest: 
- The administration of prothrombin complex 
concentrates to patients treated with vitamin K 
antagonists and presenting with active bleeding or 
undergoing urgent or emergent surgery.
- Perioperative administration of tranexamic acid 
to patients undergoing lower limb arthroplasty, 
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extensive spinal instrumentation, gynaecological 
cancer surgery, or radical prostatectomy.
- The administration of tranexamic acid to patients 
presenting with gastrointestinal bleeding due to ulcer 
or mucosal erosion.
- Perioperative administration of erythropoiesis-
stimulating agents to patients undergoing cardiac or 
gastrointestinal cancer surgery.
Grade 2B recommendations
We suggest:
- Preoperative autologous blood donation in patients 
undergoing surgery for colorectal, prostatic or hepatic 
cancer resection, generally with adjuvant treatment 
with erythropoiesis-stimulating agents, as well as in 
cardiac procedures with cardiopulmonary bypass.
- Thromboelas tography-guided  f ibr inogen 
concentrates to patients undergoing cardiac, aortic 
aneurysm repair, or radical cystectomy surgical 
procedures, as well as in obstetric haemorrhage. 
- Preoperative oral iron administration in patients 
undergoing orthopaedic or colorectal cancer surgery.
- Perioperative intravenous iron administration 
to anaemic patients scheduled for orthopaedic, 
gynaecological or gastrointestinal surgery.
- The administration of intravenous iron, without 
erythropoiesis-stimulating agents, for treating 
radiotherapy- or chemotherapy-induced anaemia in 
cancer patients.
- Fluid resuscitation in patients with severe blood losses.
Grade 2C recommendations
We suggest:
- Perioperative cell salvage in patients undergoing 
hepatic or urological cancer surgery, abdominal trauma, 
Caesarean section, or ruptured ectopic pregnancy. 
- Thromboelastography-guided administration of 
prothrombin complex concentrates to patients not on 
vitamin K antagonists and presenting with bleeding 
trauma, perioperative haemorrhage or acute liver 
failure.  
- The administration of prothrombin complex 
concentrates, instead of fresh-frozen plasma, 
to patients on vitamin K antagonists who need 
immediate reversal of anticoagulation.
- The administration of recombinant activated factor 
VII to patients presenting with severe or refractory 
haemorrhage, including intracranial haemorrhage 
and postoperative haemorrhage after cardiac or liver 
surgery.
- Postoperative intravenous iron administration 
for treating postoperative anaemia after cardiac, 
obstetrics and gynaecological or orthopaedic surgical 
procedures.
Grade 0 recommendation
We cannot make any evidence-based recommendation 
on the use of perfluorocarbon- and haemoglobin-based 
oxygen carriers as alternatives to allogeneic blood 
transfusion.
1. Background and objectives
The Spanish Consensus Statement on Alternatives 
to Allogeneic Blood Transfusion (AABT), so-called 
the Seville Document (SD), was first published in 
20061. The original purpose of the SD was to generate 
recommendations based on the best available evidence 
on AABT indications, in order to assist all professionals 
involved in the administration of both allogeneic blood 
transfusions (ABT) and AABT. The present SD update 
pursues an identical goal. Also, as in the original SD, 
the SD update defines AABT as any measure aimed 
at reducing transfusion requirements and, therefore, 
the transfusion of red blood cells, preserving the 
patient's safety at all times. For a detailed analysis, 
the measures were divided into pharmacological and 
non-pharmacological AABT.
Why did the SD 2006 consensus document need 
an update? There are several reasons that justify this 
SD update: (i) the persistent variability in the clinical 
use of AABT; (ii) the withdrawal of drugs for which 
there was a high degree of evidence in the original 
SD (e.g., aprotinin); (iii) new indications for drugs 
or devices, not covered by the original SD (e.g., 
prothrombin complex, fibrinogen and viscoelastic 
tests); (iv) warning alerts generated by government 
agencies regarding the adverse effects of some drugs 
(e.g., erythropoiesis-stimulating agents); (v) the 
limitations of Delphi methodology used in the first SD 
edition, as this methodology directly links the level 
of evidence to grade of recommendation, resulting in 
recommendations always being formulated positively, 
sometimes leading to confusion among the readers; 
and (vi) the incorporation of the Spanish Society of 
Hospital Pharmacy as a new, active member of the 
consensus.
The recommendations of the updated SD are aimed 
at surgical, trauma or critically ill patients with blood 
loss who may require the use of pharmacological or 
non-pharmacological AABT. As in the original SD, 
the updated SD only contemplates the alternatives 
to transfusion of packed red blood cell concentrate 
(PRBC). For the purpose of this document, we define 
the transfusion rate as the number of transfused PRBC 
units or the percentage of transfused patients. The main 
question that arises in each item is formulated, positively 
or negatively, as: "the AABT in question reduces/does 
not reduce the transfusion rate". Recommendations 
on the use of a particular AABT to reduce transfusion 
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rates were graded according to the Grades of 
Recommendation, Assessment, Development, and 
Evaluation (GRADE) methodology2-4.
2. Methodology
2.1. Scientific Societies and expert panel
This updated SD was produced by a panel of 40 
professionals convened by six Spanish Scientific 
Societies involved in health care: Spanish Society 
of Anaesthesiology and Reanimation (SEDAR), 
Spanish Society of Hospital Pharmacy (SEFH), 
Spanish Society of Haematology and Haemotherapy 
(SEHH), Spanish Society of Critical Care Medicine 
SEMICYUC), Spanish Society of Thrombosis and 
Haemostasis (SETH) and Spanish Society of Blood 
Transfusion and Cellular Therapy (SETS). There were 
one general coordinator, one general vice-coordinator, 
nine topic coordinators (including the general 
coordinator), 25 collaborators, and six observers 
(the Presidents of the different Societies). With the 
exception of the members convened by SEFH, the 
panel composition for this updated SD did not differ 
substantially from that of the original SD1. All six 
Societies endorsed the recommendations formulated 
in the SD update.
2.2. GRADE methodology
The available evidence on the efficacy and safety of 
AABT was analysed according to GRADE methodology. 
We chose GRADE methodology because it has a 
number of advantages over other methodologies, 
such as the Delphi methodology, including: clear 
separation between quality of evidence and strength 
of recommendation; explicit, comprehensive criteria 
for downgrading and upgrading quality of evidence 
ratings; transparent process of moving from evidence to 
recommendations; explicit acknowledgement of values 
and preferences; and clear, pragmatic interpretation of 
strong versus weak recommendations for clinicians, 
patients, and policy makers, as well as for guidelines 
development.
Strong recommendations (Grade 1) may be A, 
B or C depending on the quality of evidence (high, 
moderate, low or very low). In all cases of strong 
recommendation, benefits clearly outweigh risks and 
burden (a positive recommendation), or vice versa (a 
negative recommendation). However, the implications 
are different. A Grade 1A or 1B recommendation may 
be applied to most patients, in most circumstances and 
without reservation, whereas a grade 1C recommendation 
may change when evidence of higher quality become 
available. Weak recommendations (Grade 2) may also 
be A, B or C depending of the quality of evidence. 
Grade 2A and 2B recommendations mean that benefits 
are closely balanced with risks and burden and that 
the best action may differ depending on circumstances 
or patients' or societal values. In contrast, a Grade 2C 
recommendation means that there is uncertainty in the 
risk to benefit balance and that other alternatives may 
be equally reasonable. 
These differences in strength are reflected by the 
wording of the recommendations. Thus, when making 
a strong recommendation, we use the terminology, "We 
recommend..."  or "We do not recommend...". However, 
when making a weak recommendation, we used a less 
definitive wording, such as, "We suggest..."4. For each 
particular AABT, the target patient population is defined, 
details on implementation and doses are given, when 
appropriate, and a safety statement is always included4. 
Finally, it should be borne in mind that for some 
AABT and/or patient populations no evidence-based 
recommendation could be given (Grade 0).
3. Non-pharmacological alternatives to 
allogeneic blood transfusion 
The non-pharmacological AABT include restrictive 
transfusion therapy, preoperative autologous blood 
donation, acute normovolaemic haemodilution, 
perioperative red cell salvage and assessment of 
haemostasis by thromboelastography.
3.1. Restrictive transfusion therapy in non-bleeding 
patients
Allogeneic blood is an increasingly scarce and 
expensive resource; there is a lack of evidence 
regarding the efficacy of ABT to increase tissue oxygen 
consumption or reduce tissue oxygen debt in selected 
patients; and, more importantly, ABT is not risk-free, 
as there is an association between ABT and increased 
morbidity and mortality. All these have prompted several 
Scientific Societies to recommend a restrictive approach 
when using ABT. Thus, the level of haemoglobin 
(Hb) below which a PRBC unit is transfused (i.e. the 
"transfusion trigger") should be intimately related to 
the patient's ability to tolerate normovolaemic anaemia 
and, consequently, to his/her cardiopulmonary reserve.
 
3.1.1. Critically ill, trauma and/or surgical patients, 
without cardiac and/or central nervous system 
dysfunction
We recommend the use of restrictive transfusion 
therapy, maintaining haemoglobin concentrations 
between 70 g/L and 90 g/L, to reduce the transfusion 
rate. Grade 1A.
Randomised controlled trials (RCT) in euvolaemic, 
critically ill adults5 and paediatric patients6, as well 
as in patients undergoing vascular7 or orthopaedic8 
surgery and in those presenting with acute upper 
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gastrointestinal bleeding9, have documented that the 
majority of such patients can tolerate haemoglobin 
concentrations as low as 70. Nevertheless, patients' 
tolerance of normovolaemic anaemia depends on their 
cardiopulmonary reserve, the volume and speed of blood 
loss, and the acute or chronic onset of anaemia.
3.1.2. Critically ill, trauma and/or surgical patients, 
with cardiac and/or central nervous system 
dysfunction
We recommend the use of restrictive transfusion 
therapy, maintaining haemoglobin concentrations 
between 80 g/L and 100 g/L, to reduce the transfusion 
rate. Grade 1A.
It has been documented that patients who present with 
ischaemic heart disease and/or have undergone cardiac 
surgery, have a poor tolerance of anaemia10. Anaemic 
patients with symptomatic ischaemic heart disease and/
or brain dysfunction may require higher haemoglobin 
levels. In elderly anaemic patients (haematocrit <33%) 
with myocardial infarction, the correction of anaemia 
with PRBC transfusion improves the clinical outcome11. 
The efficacy of PRBC is linked to the severity of anaemia 
and myocardial ischaemia. In anaemic patients (Hb <120 
g/L) with ST elevation, PRBC transfusion improves the 
clinical outcome12. Conversely, in patients with mild 
anaemia, as well as in those with ischaemia but without 
ST elevation, PRBC transfusion may worsen the clinical 
outcome10. It has been shown that patients who undergo 
cardiac surgery and have no signs of perioperative 
ischaemia tolerate haemoglobin levels of 80 g/L without 
increased postoperative morbidity or mortality10,13,14. A 
recent RCT15 documented that in elderly patients, who had 
either a history of or risk factors for cardiovascular disease 
and had undergone surgery for hip fracture, restrictive 
transfusion therapy (transfusions given for symptoms of 
anaemia or at the physician's discretion for a Hb level 
<80 g/L), as compared with a liberal strategy (transfusions 
given below a Hb threshold of 100 g/L), did not increase 
rates of postoperative morbidity or mortality.
Given its high metabolic rate, the brain has little 
tolerance of anaemia, requiring a continuous and abundant 
supply of oxygen. As haemoglobin-bound oxygen is 
the main component of oxygen transport, anaemia may 
adversely affect brain function in patients with traumatic 
brain injury, subarachnoid haemorrhage or stroke. It is 
likely, although not definitely documented, that anaemic 
patients with severe brain dysfunction may require higher 
haemoglobin levels than those without it16,17.
3.1.3. Safety
In euvolaemic surgical patients, almost all RCT 
conducted to date have shown that the use of restrictive 
transfusion therapy does not increase the rates of 
postoperative morbidity or mortality or the length of 
hospital stay, while it does reduce both the percentage of 
transfused patients and the volume of allogeneic blood 
administered. Critically ill patients, especially those 
with acute brain and/or cardiac dysfunction, may have 
worse outcomes if they are exposed to severe anaemia. 
However, although anaemia may increase morbidity and 
mortality, PRBC transfusion does not necessarily revert 
the deleterious effects of anaemia.
3.1.4. Summary
The majority of trauma, critically ill and/or surgical 
patients can tolerate haemoglobin levels of 70 g/L. 
However, for those presenting with acute cardiac and/or 
central nervous system dysfunction, a haemoglobin 
level of at least 80 g/L may be required. In any 
case, transfusion decisions should be individualised 
according to patient's co-morbidity, symptoms and 
haemoglobin concentration.
3.2. Preoperative autologous blood donation 
Preoperative autologous blood donation (PABD) is a 
modality of autotransfusion consisting in the withdrawal 
of one or several units of the patient's own blood, in 
the days or weeks prior to the intervention. These units 
undergo serological screening and storage, and may be 
reinfused into the patient during the procedure or in the 
immediate postoperative period.
3.2.1. Major orthopaedic surgery
We do not recommend the routine use of preoperative 
autologous blood donation to reduce transfusion rates 
in procedures usually requiring two or fewer units of 
packed red blood cells per patient. Grade 1B.
In adult patients undergoing major orthopaedic 
surgery (knee, hip or spine), data from RCT and 
observational studies showed a 20% reduction of the 
transfusion rate. However, in most of these studies 
transfusion criteria were not established. In addition, 
60-70% of patients undergoing PABD received 
some type of transfusion, autologous or allogeneic, 
and 40% of the deposited units were not used18-22. 
Preoperative administration of recombinant human 
erythropoietin(rHuEPO)23 or perioperioperative red 
cells salvage (PRCS)24 is at least as effective as PABD 
in reducing ABT requirements.
We recommend the use of preoperative autologous 
blood donation to reduce transfusion rates in procedures 
usually requiring three or more units of packed red cells 
per patient, preferably with adjuvant treatment with iron 
and/or recombinant human erythropoietin. Grade 1C.
Observational studies in patients undergoing 
orthopaedic procedures associated with major bleeding, 
such as revision of total hip arthroplasty and correction 
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of scoliosis, have shown that PABD significantly reduces 
the transfusion rate, although up to 30% of PABD 
units were not used25,26. In small studies of lower limb 
prosthetic surgery, the use of rHuEPO as an adjuvant 
to PABD further reduced the use of ABT, although this 
strategy was not cost-effective1. In addition, in patients 
undergoing scoliosis or complex spinal surgery, PABD 
with adjuvant treatment with rHuEPO facilitated the 
donation of the requested autologous units and resulted 
in a significantly decreased exposure to ABT when 
compared with PABD alone27,28. Furthermore, the 
concomitant intravenous (IV) administration of iron 
may enhance the bone marrow response to rHuEPO, 
reducing the dose of the rHuEPO required and, thereby, 
improving cost-effectiveness29.
3.2.2. Elective cardiac surgery
We suggest the use of preoperative autologous blood 
donation to reduce transfusion rates in elective cardiac 
surgical procedures with cardiopulmonary bypass. 
Grade 2B.
Data from two large observational studies indicate 
that preoperative donation of two autologous units was 
the most effective strategy to prevent ABT with lower 
incremental costs22,30. In some studies, adjuvant treatment 
with rHuEPO improved the efficacy of PABD in cardiac 
surgery procedures, both in adults and children1.
3.2.3. Oncological surgery
We suggest the use of preoperative autologous 
blood donation to reduce transfusion rates in surgical 
procedures for solid cancer resection. Grade 2B.
The results of various RCT and observational studies 
suggested that PABD may reduce ABT requirements by 
as much as 30% in colo-rectal cancer surgery31, radical 
prostatectomy32, and hepatic resections33. Once again, 
adjuvant rHuEPO treatment enhanced the efficacy of 
PABD in reducing ABT rates31-33.
3.2.4. Safety
The use of PABD is contraindicated permanently 
in seropositive patients and patients with serious 
cardiovascular disease, and temporarily in those with 
active bacterial infection, a haemoglobin level <100 g/L 
or body weight <10 kg34. The results of a meta-analysis18 
indicated that the use of PABD reduced transfusion rates 
without increasing postoperative morbidity or mortality. 
However, it should be borne in mind that the incidence of 
adverse effects during PABD is higher than that observed 
for altruistic blood donation and that PABD increases the 
risk of receiving any type of transfusion. It is mandatory 
by law to discard unused units as well as seropositive 
units and to communicate any adverse event of PABD 
transfusion to the national haemovigilance system35.
3.2.5. Summary
The use of PABD would be indicated in patients 
undergoing elective surgical procedures in which the 
risk of transfusion is greater than 30-50% (usually 
with a preoperative Hb <145 g/L), patients for whom 
compatible ABT is difficult to find, and those who refuse 
to receive ABT. The risk of receiving ABT is reduced 
further in PABD patients receiving adjuvant rHuEPO 
plus iron and undergoing surgical procedures that require 
the predeposit of three or more autologous units. Finally, 
it must be remembered that the PABD programme 
should only be implemented in those centres in which 
a scheduled surgery date is guaranteed.
3.3. Acute normovolaemic haemodilution 
Acute normovolaemic haemodilution (ANH) consists 
of the extraction and anticoagulation of a predicted 
volume of blood from the patient and its simultaneous 
exchange for a cell-free crystalloid and/or colloid 
solution to maintain normovolaemia. Even though 
extreme ANH and other types of haemodilution have 
been used, moderate ANH (final haematocrit 25-30%) is 
the preferred technique. It is used in patients undergoing 
major surgical procedures with moderate-to-severe blood 
loss, and is usually performed after the induction of 
anaesthesia, before the intraoperative phase of bleeding.
3.3.1. Major surgical procedures 
We do not recommend the routine use of acute 
normovolaemic haemodilution, as a single blood-
sparing technique, given its low effectiveness at reducing 
the transfusion rate. Grade 1B.
The results of two meta-analyses of 42 RCT 
showed that the use of ANH resulted in a small, 
significant reduction in transfusion rate18,36. However, the 
effectiveness of ANH was virtually eliminated in studies 
in which a transfusion protocol was applied and when 
partnered or compared with other AABT (e.g., PABD, 
tranexamic acid)18,36,37.
3.3.2. Safety
This AABT should only be used in those institutions 
that can implement logistics for blood removal and 
volume replacement without detracting from patient 
care, and following the recommendations of published 
guidelines38. Bags of blood can be kept in the operating 
theatre at room temperature for a maximum of 6 hours 
and reinfused in reverse order of their removal. Although 
in two meta-analyses ANH was not associated with 
increased risks of morbidity and mortality, the quality 
of the evidence in this regard is moderate to low36,37. In 
adult patients undergoing cardiac surgery, ANH has been 
associated with increased rates of kidney failure39 and 
disorders of psychomotor development in children40. In 
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contrast, the use of ANH was associated with reduced 
rates of postoperative infection in people undergoing 
orthopaedic surgery41.
3.3.3. Summary
Most of the studies did not show a significant reduction 
of transfusion rate, although ANH has contributed to 
the concept of tolerance to low haemoglobin levels in 
low-risk patients. Therefore, despite its low cost, ANH 
should only be used in association with other AABT 
in selected patients, except in those centres in which 
no other AABT can be implemented. The available 
evidence on other modalities of haemodilution, such as 
moderate hypervolaemic haemodilution or augmented 
acute haemodilution, is insufficient to be able to make 
any recommendation1.
3.4. Perioperative red cell salvage
Perioperative red cell salvage (PRCS) is defined 
as the collection of the patient's blood in surgical 
procedures in which blood loss is significant. During 
surgery, intraoperative cell salvage is performed 
using devices that aspirate, anticoagulate, wash and 
concentrate the blood shed from the surgical field, 
which is returned to patients as PRBC in saline. After 
surgery, postoperative cell salvage consists of the 
collection and reinfusion of blood lost through the 
wound drains. When intraoperative cell salvage is 
not indicated, postoperative cell salvage is usually 
performed using devices that collect and return 
unwashed filtered shed blood.
3.4.1. Major orthopaedic surgery
a) Total knee or hip arthroplasty
We recommend the use of perioperative red cell 
salvage, reinfusing filtered and/or washed salvaged 
blood, to reduce the transfusion rate. Grade 1B. 
In patients undergoing surgery for primary total 
knee arthroplasty42,43 or total hip arthroplasty44,45, 
postoperative recovery and reinfusion of washed or 
filtered shed blood reduced the absolute risk of receiving 
ABT by 20% (11% versus 30%), but not the number 
of ABT units per transfused patient. Postoperative 
cell salvage with washed blood was also effective in 
reducing the transfusion rate in revisions of total hip 
arthroplasties, especially if it was associated with other 
AABT46.
b) Spine surgery
We recommend the use of perioperative red cell 
salvage, within a multimodal blood management 
programme, for reducing the transfusion rate in 
patients undergoing surgery for scoliosis or complex 
degenerative spine pathology. Grade 1C.
In instrumental lumbar or lumbo-sacral spine 
surgery, with or without iliac crest bone autografting, 
postoperative cell salvage significantly reduced the 
volume of ABT, but not the percentage of patients who 
underwent ABT47. In surgery for correction of scoliosis, 
in which up to 90% of the patient's estimated blood 
volume can be lost, PRCS alone or associated with other 
AABT, significantly reduces transfusion rate48,49.
3.4.2. Cardiac surgery
We recommend the use of perioperative red cell 
salvage to reduce transfusion rates in elective cardiac 
surgical procedures with cardiopulmonary bypass. 
Grade 1B.
In cardiac surgery with cardiopulmonary bypass 
(CPB), salvage, washing and reinfusion of blood from 
the surgical field, the cardiotomy reservoir and the 
postoperative chest drainage reduced the percentage of 
patients exposed to ABT when compared to a control 
group, but not the number of ABT units infused per 
patient50. However, PRCS was not effective if it was 
limited to processing pericardial suction51 or used in 
cardiac surgery without CPB52.
3.4.3. Major vascular surgery
We recommend the use of perioperative red cell 
salvage to reduce transfusion rates in vascular surgical 
procedures for abdominal aorta aneurysm repair. 
Grade 1B.
Several studies on elective surgery for repair of an 
abdominal aorta aneurysm showed that intraoperative 
cell salvage reduced, by 40%, the absolute risk of 
exposure to ABT and the ABT volume when compared 
to control management53. It has been estimated that 
intraoperative cell salvage is cost effective when 
blood loss exceeds 800 mL. In surgery to repair a 
ruptured abdominal aorta aneurysm, intraoperative 
cell salvage reduced ABT requirements by three units 
per patient53,54. In elective and ruptured abdominal 
aorta aneurysm, the use of an endovascular prosthesis 
reduced bleeding and transfusion requirements in 
comparison with open surgery, although the role of 
intraoperative cell salvage in this setting has not been 
sufficiently studied.
3.4.4. Other surgical procedures
We suggest the use of perioperative red cell salvage, 
with washing and filtering and/or irradiation of salvaged 
blood, for reducing transfusion rates in surgical 
resection of hepatic or urological cancers, Caesarean 
section or ruptured ectopic pregnancy. Grade 2C.
Several RCT and observational studies suggest 
that PRCS may reduce transfusion rates in patients 
undergoing liver transplantation for hepatocellular 
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carcinoma or cirrhosis55, radical prostatectomy56, 
Caesarean section57, rupture of ectopic pregnancy58, or 
abdominal trauma59.
3.4.5. Safety
Data from clinical studies conducted in different 
types of urgent or elective surgery clearly showed that 
PRCS did not increase either the risk of postoperative 
morbidity or mortality or the length of hospital stay. 
However, some serious adverse effects have been 
reported, especially coagulopathy, when large volumes 
of recovered and processed blood are transfused. As for 
orthopaedic surgery, although serious adverse effects 
have been barely detected, more than 1,000 mL of 
unwashed filtered blood should not be reinfused60. In 
contrast, the results of a systematic review indicate that 
reinfusion of salvaged unwashed filtered blood after 
cardiac procedures is not recommended18. The indication 
for PRCS in cancer surgery and Caesarean section is 
controversial. In cancer surgery, the results of a recent 
meta-analysis showed that PRCS did not increase the 
incidence of metastasis or cancer recurrence61.
3.4.6. Summary
Intraoperative cell salvage would be indicated in 
patients undergoing elective surgery in which a blood 
loss of more than 1,500 mL is expected and at least the 
equivalent of 1.5-2 units of PRBC can be recovered. 
On the other hand, the use of postoperative salvage 
and reinfusion of unwashed filtered blood would be 
restricted to patients with haemoglobin <14 g/dL 
undergoing elective prosthetic surgery in which a 
postoperative blood loss volume between 500 mL and 
1,000 mL is expected, and at least the equivalent of 1 
unit of PRBC can be recovered1. It must be stressed 
that the recommendations given in this section are 
limited by the poor methodological quality of many of 
the studies analysed, which generally involved a small 
number of patients (less than 60 per arm). In addition, 
as the trials were not blinded and lacked adequate 
concealment of treatment allocation, transfusion 
practices may have been influenced by knowledge of 
the patient's treatment status, thus biasing the results 
in favour of PRCS. Finally, it is worthy noting that 
the contribution of PRCS to ABT reduction decreased 
when a transfusion protocol was implemented.
3.5 Point-of-care coagulation testing:   
thromboelastography
Thromboelastrography (TEG) provides a global 
evaluation of the viscoelastic properties of a clot (cellular 
model of blood coagulation), displays the results 
graphically and enables the analysis of clot formation 
and lyses in less than 10 minutes at the point-of-care (e.g. 
at the bedside). Thus, TEG has significant advantages 
compared to conventional coagulation tests; namely, 
rapid results to guide haemostatic therapy, leading 
to early clinical decisions, and overall evaluation of 
coagulation in whole blood62,63. Up to 35% of the bleeding 
trauma patients present with abnormal coagulation tests 
upon hospital admission. The so-called "acute traumatic 
coagulopathy"64 is an independent predictor of poor 
outcome and, if present,  needs to be treated early and 
aggressively. On the other hand, surgical patients may 
also develop different coagulation disorders, which 
should be managed on an individual basis. TEG enables 
individualised administration of blood components 
(plasma and platelet concentrates) and clotting factor 
concentrates (fibrinogen and prothrombin complex).
 
3.5.1. Bleeding in patients with severe trauma
We recommend the use of thromboelastography to 
guide the replacement of blood clotting factors and 
reduce the transfusion rate. Grade 1C.
Patients with bleeding injuries may develop 
early clotting alterations (within 30 minutes 
following trauma), including hypocoagulability, 
hypercoagulab lity or hyperfibrinolysis62,63. At least 20 
studies have documented that the use of TEG enables 
more efficient management of coagulation and may 
reduce transfusion rate62,64.
3.5.2. Bleeding in surgical patients
 We recommend the use of thromboelastrography 
to guide the replacement of blood clotting factors and 
reduce the transfusion rate. Grade 1C.
A retrospective study that included more than 
3,000 patients undergoing cardiovascular surgery 
documented that TEG significantly decreased the 
rates of transfusion and thromboembolic events65. 
Retrospective studies involving small numbers of 
patients undergoing vascular, liver or obstetric surgery 
concluded that TEG reduced transfusion rates and 
enabled early treatment of coagulation disorders66,67.
3.5.3. Safety
The use of TEG carries no risks for the patient. 
However, as TEG does not evaluate platelet function, 
patients with platelet dysfunction should be assessed 
with other technologies63.
3.5.4. Summary
TEG is a useful technique for the early assessment 
of coagulation disorders and facilitates selective 
administration of blood components and clotting factors. 
Although its use is associated with a significant decrease 
in ABT, it does not diminish the high mortality rate of 
patients with severe bleeding67.
All rights reserved - For personal use only 
No other uses without permission
© 
SIM
TI 
Se
rvi
zi 
Srl
592
Leal-Noval SR et al
Blood Transfus 2013; 11: 585-610  DOI 10.2450/2013.0029-13
4. Pharmacological alternatives to allogeneic 
blood transfusion
Pharmacological AABT include measures to 
decrease bleeding, stimulate erythropoiesis and improve 
oxygen transport. 
Pharmacological alternatives to decrease 
bleeding
The reduction of perioperative blood loss is essential 
to decrease a patient's exposure to ABT. This reduction 
may be achieved through proper management of 
platelet anti-aggregant and anticoagulation therapy, 
maintenance of normothermia, use of controlled, 
induced or permissive hypotension, meticulous surgical 
haemostasis and, when possible, minimally invasive 
surgical techniques and the use of low-vacuum drains. 
Finally, the administration of drugs that promote clot 
formation, ensure clot stability and/or delay clot lysis 
should be evaluated.
4.1. Prothrombin complex concentrates
Prothrombin complex concentrates (PCC) are plasma 
derivatives that contain varying amounts of clotting factors 
II, IX and X ("three-factor PCC", marketed in the USA) 
or clotting factors II, VII, IX and X ("four-factor PCC", 
marketed in Europe). The three "four-factor PCC" sold 
in Spain have similar efficacy, but they differ slightly in 
composition. To prevent thrombin formation, PCC contain 
protein C, protein S, antithrombin III and/or heparin68.
4.1.1. Patients being treated with vitamin K antagonists 
and presenting with active bleeding or requiring 
urgent or emergent surgery
We suggest the administration of prothrombin 
complex concentrate to reduce bleeding and/or 
transfusion rate. Grade 2A.
Within 10 to 30 minutes after administration of a 
PCC, virtually all patients achieve normalisation of their 
International Normalised Ratio (INR) values69-71. When 
PCC administration was aimed to prevent bleeding 
in patients who were to undergo surgery or invasive 
procedures or to decrease bleeding in patients with 
active haemorrhage, most of the studies documented its 
efficacy in achieving these goals72. Clinical guidelines 
suggest the use of four-factor PCC in bleeding patients 
treated with vitamin K antagonists (VKA), regardless 
of INR value73. In surgical patients, PCC may be 
preferable to rFVIIa and/or fresh-frozen plasma (FFP)74. 
However, the small number of studies, the retrospective 
nature of most of them, the low numbers of patients 
included, the concomitant treatment with FFP or other 
pro-haemostatic drugs, the absence of control groups, 
and methodological differences do not allow solid 
conclusions to be drawn.
4.1.2. Patients being treated with vitamin K antagonists 
and presenting with intracranial haemorrhage
We recommend the administration of prothrombin 
complex concentrate to reduce bleeding. Grade 1C.
Intracranial haemorrhage is the most serious event 
associated with anticoagulation with VKA. The risk of 
intracranial haemorrhage doubles for every point increase 
in INR. The rates of haematoma expansion, neurological 
sequelae and mortality are higher in VKA-associated 
intracranial haemorrhage than in intracranial haemorrhage 
of other aetiologies75-78. The mortality rate within the first 
24 hours can reach 33%79,80. The INR is corrected and 
bleeding controlled more effectively in patients treated 
with PCC than in those treated with FFP81,82. However, 
the rates of mortality and sequelae remain consistently 
high, regardless of the treatment chosen79,80.
4.1.3. Patients not being treated with vitamin K 
antagonists and presenting with coagulopathy in 
the setting of trauma, perioperative haemorrhage 
or acute liver failure
We suggest the administration of prothrombin 
complex concentrate to reduce bleeding and/or 
transfusion rate. Grade 2C.
Bleeding in trauma patients. Generally patients with 
massive haemorrhage receive more PRBC units than 
FFP units (ratio 3:1 or higher). Although controversial, 
data from trauma patients with critical bleeding in 
the military context have documented that mortality 
improved when patients received similar amounts of 
PRBC, FFP and platelet concentrates (i.e. a 1:1:1 ratio), 
thus suggesting the need to provide large amounts of 
clotting factors from the onset of bleeding83,84. As a 
PCC quickly delivers large amounts of clotting factors, 
early PCC administration may reduce transfusion 
requirements85. 
Bleeding in surgical patients. PCC administration 
is associated with decreased transfusion requirements 
in the perioperative period86, especially in patients 
undergoing cardiac surgery65. 
Acute liver failure. One observational study suggests 
that PCC could be useful in the prophylaxis or treatment 
of bleeding in patients with deficiency of liver-dependent 
clotting factors secondary to acute liver failure87.
4.1.4. Patients being treated with vitamin K 
antagonists and requiring immediate reversal 
of anticoagulation: prothrombin complex 
concentrate versus fresh-frozen plasma or 
recombinant activated factor VII
We suggest that prothrombin complex concentrate 
is superior to fresh-frozen plasma or recombinant 
activated factor VII for reducing bleeding and/or 
transfusion rate. Grade 2C.
All rights reserved - For personal use only 
No other uses without permission
© 
SIM
TI 
Se
rvi
zi 
Srl
593
Blood Transfus 2013; 11: 585-610  DOI 10.2450/2013.0029-13
Seville Document Update 2013
FFP contains varying amounts of all coagulation 
factors. Although the optimal FFP dose has not been 
established, a dose of 15 mL/kg is usually recommended. 
However, doses as high as 30 mL/kg may be needed 
to provide optimal amounts of clotting factors88,89. 
Compared with FFP, PCC has several advantages: (i) 
greater content of liver-dependent clotting factors, but 
lacks fibrinogen and factor XIII; (ii) no need for group 
matching (whereas this is necessary for FFP); (iii) 
faster administration (FFP must be thawed, delaying its 
administration); (iv) it corrects the INR more quickly 
and effectively does than FFP (less than 30 minutes 
with PCC); and (v) smaller volumes necessary (at the 
suggested dose, at least 1,000 mL of FFP are needed for 
a 70 kg patient, which may lead to transfusion-associated 
cardiovascular overload [TACO] and transfusion-related 
acute lung injury [TRALI])69-71. Most guidelines73,74 and 
observational studies81,82 suggest that PCC is superior to 
FFP in controlling VKA-induced haemorrhagic events. In 
mice with VKA-induced intracranial haemorrhage, PCC 
or FFP was more effective than rFVIIa at halting expansion 
of the haematoma90. Although the administration of 
rFVIIa reduced the size of the haematoma in patients with 
intracranial haemorrhage, mortality remained invariably 
high. In addition, the high rate of thromboembolic events 
has discouraged the routine use of rFVIIa in VKA-treated 
patients with critical haemorrhage91.
4.1.5. Dosage
In patients with intracranial haemorrhage, the 
administration of 25-50 IU/kg of PCC slows the 
expansion of the haematoma, corrects the INR in less 
than 30 minutes and enables surgical control of the 
haematoma80. In general, either fixed or individualised 
doses can be used. A recent study found no advantage 
from using individualised doses, recommending a single 
fixed dose of 1,000 IU PCC for all situations92. However, 
most authors recommend individualised doses (based on 
the patient's weight and current and target INR), which 
vary between 15-50 IU/kg. In all cases, administration of 
PCC should be supplemented with 5-10 mg of vitamin K, 
IV. Generally, the PCC dosage is based on the percentage 
of plasma clotting factors, so the INR must be converted 
to this percentage (Table I). The dose is then calculated 
using the equation: 
units of factors of PCCP = 
(target level of factors [%] – current level of factors [%])
× body weight [kg].
For example, for a man weighing 80 kg with a current 
INR of 7.5 (5% of plasma clotting factors) and a target 
INR of 1.5 (40% of plasma clotting factors), the PCC 
dose would be (40–5)×80=2,800 IU 93.
4.1.6. Safety
Variable, but low rates of thrombo-embolic events, 
especially in arterial territories (stroke, myocardial 
infarction, pulmonary embolism) have been reported in 
patients treated with PCC65,70,94. However, in the majority 
of cases, a cause-effect relationship between PCC 
administration and increased rates of clinically relevant 
thromboembolic phenomena has not been documented. 
Most Authors consider PCC as a safe drug94. 
 
4.1.7. Summary 
As in other recent clinical practice guidelines, 
we suggest the administration of PCC for patients 
being treated with VKA who present with bleeding or 
require invasive procedures, although this is a weak 
recommendation based on data from retrospective 
studies involving few patients (Grade 2C). However, 
a strong recommendation is to administer PCC to 
VKA-treated patients with intracranial haemorrahge 
(Grade 1C), since several retrospective studies and at 
least two prospective studies have documented that 
administration of PCC in this context resulted in a 
decreased rate of haematoma expansion. Finally, PCC 
could potentially be useful in bleeding patients not 
being treated with VKA (Grade 2C).
4.2. Fibrinogen
Adequate levels of fibrinogen (1.5-4.5 g/L) are 
critical to achieve effective haemostasis. Fibrinogen 
facilitates platelet aggregation and, when activated 
by thrombin, gives rise to fibrin polymers, which are 
the basis of clot formation66. Severe haemorrhage 
involves the loss of coagulation factors, including 
fibrinogen. Intensive resuscitation with crystalloid 
solutions further dilutes existing clotting factors. In 
addition, colloids may interfere with the formation of 
an effective clot, by altering its firmness and stability. 
Both mechanisms (loss and dilution of clotting factors) 
lead to coagulopathy. The presence of coagulopathy is an 
independent risk factor for poor clinical outcome62-66. In 
addition, pre-operative fibrinogen levels are predictive 
of perioperative bleeding66,95,96.
Table I - Conversion of INR values to % of plasma clotting 
factors.
INR % plasma clotting factors
Supra-therapeutic range
>5 5
4-4.9 10
Therapeutic range
2.6-3.2 15
2.2-2.5 20
1.9-2.1 25
Infra-therapeutic 
range 
1.7-1.8 30
1.4-1.6 40
1.0-1.4 100
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Fibrinogen seems to be the coagulation factor that 
first reaches a critically low level (<1 g/L) drung active 
bleeding. There are three ways to replace fibrinogen: 
FFP, cryoprecipitate and fibrinogen concentrate. The 
compound most commonly used in Spain is fibrinogen 
concentrate, which is also a plasma derivative, but unlike 
FFP and cryoprecipitate, does not require cross-matching 
and is administered quickly  (up to 6 g can be given in 
less than 3 minutes)97,98.
4.2.1. Patients with traumatic bleeding 
We recommend the administration of fibrinogen 
concentrates to reduce bleeding and/or transfusion 
rate. Grade 1C. 
European guidelines on traumatic bleeding 
recommend the administration of fibrinogen in all 
cases of severe bleeding, in which TEG shows a 
fibrinogen deficiency or plasma fibrinogen is below 
2 g/L99. Recent reviews of retrospective studies of 
patients with bleeding trauma conclude that TEG-
guided fibrinogen administration, with or without PCC, 
reduces the transfusion rate and may improve clinical 
outcome62-67,95,96,100,101.
4.2.2. Bleeding in surgical patients
We suggest the administration of fibrinogen 
concentrates to reduce bleeding and/or transfusion 
rate. Grade 2B.
In patients undergoing surgery to repair a ruptured 
abdominal aortic aneurysm, administration of massive 
amounts of FFP significantly reduced mortality rate 
from 39% to 15%, suggesting that early administration 
of clotting factors may improve the clinical outcome102. 
In addition, preoperative and postoperative infusion of 
high doses of fibrinogen (6 g in 2 minutes) increased 
clot firmness and reduced bleeding and transfusion 
requirements102. In a retrospective study of more than 
3,000 patients undergoing cardiac surgery, TEG-guided 
administration of fibrinogen and PCC reduced the rates 
of transfusion and thromboembolic events65. A recent 
RCT documented that haemostasis is more effectively 
restored with fibrinogen and FFP than with FFP 
alone103. One RCT involving 20 patients undergoing 
radical cystectomy documented a significantly lower 
transfusion rate in the group treated with fibrinogen104. A 
series of six cases shown that combined administration 
of fibrinogen and other blood products may control 
bleeding in patients with obstetric haemorrhage105.
4.2.3. Dosage
Fresh-frozen plasma contains approximately 2 g/L 
of fibrinogen; therefore, large volumes of FFP (2 L) 
are required to increase fibrinogen levels by 1 g/L. The 
concentration of fibrinogen  is higher in cryoprecipitate 
than in FFP66,95. There is no agreement on a standard 
fibrinogen dose. Prophylactic doses of 2 g are given 
before surgery and doses of 6 g have been given in 
ongoing severe bleeding97,101, although the most usual 
dosage is 2-4 g. 
The fibrinogen dose can be calculated using the 
following formula66:  
doses of fibrinogen = 
target fibrinogen increment (g/L) × plasma volume (L).  
The plasma volume can be estimated to be 0.04 L/Kg. 
As an example, 5.6 g of fibrinogen are required to raise 
the plasma fibrinogen concentration from 1 g/L to 3 g/L 
in a 70 kg bleeding patient (2×0.04×70 = 5.6).
4.2.4. Safety
Fibrinogen is considered a safe drug96. However, its 
use has been associated with increased risks of coronary 
ischemia66 and arterial and venous thromboembolic events 
when high doses are administered (up to 12 g)106. Despite 
being a plasma derivative, transmission of blood-borne 
infections have not been described with fibrinogen.
4.2.5. Summary
The level of fibrinogen is critical to achieve 
effective haemostasis, since it is the coagulation factor 
that first reaches a critically low level (<1 g/L) during 
severe bleeding. Observational studies and case series 
suggest that early administration of fibrinogen can be 
effective in reducing the transfusion rate. Fibrinogen is 
often administered together with FFP and PCC, which 
prevents a proper assessment of its effectiveness. 
Administration of fibrinogen should ideally be guided 
by bed-side TEG rather than by conventional laboratory 
tests107. However, large RCT are needed before 
recommending its generalised use for the treatment of 
acquired fibrinogen deficiency in critical bleeding108.
4.3. Synthetic antifibrinolytic agents
Within this pharmacological group, we will discuss 
the efficacy and safety of tranexamic acid (TXA) 
and epsilon-aminocaproic acid (EACA). We will not 
consider the use of aprotinin, as it has been withdrawn 
from the market. TXA and EACA are synthetic lysine 
analogues that competitively inhibit the binding of 
plasminogen to lysine residues on the fibrin surface, 
thus preventing its conversion into active plasmin. TXA 
is 10 times more potent than EACA.
4.3.1. Major orthopaedic surgery
We suggest the administration of tranexamic acid 
to reduce perioperative blood loss and/or transfusion 
rate. Grade 2A.
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In several studies, with explicit transfusion 
protocols, in patients undergoing total hip arthroplasty109 
or total knee arthroplasty110, IV administration of TXA 
reduced the volume of perioperative blood loss and 
the requirements for ABT by as much as 25%. Topical 
TXA, as irrigation or intra-joint injection, also reduced 
postoperative bleeding, but its effect on transfusion rate 
was less evident111. In spine surgery, primarily scoliosis, 
TXA administration, in combination with other AABT, 
resulted in a  dose-dependent reduction of bleeding 
volume and ABT volume, but generally did not affect 
the percentage of patients who received ABT112-114.
We do not recommend the administration of 
ɛ-aminocaproic acid for reducing perioperative blood 
loss and/or transfusion rate. Grade 1B.
Results of a meta-analysis did not show that EACA 
has a beneficial effect on reducing the transfusion rate 
in patients undergoing orthopaedic surgery (RR: 0.73; 
95% CI 0.20-1.73)115.
4.3.2. Cardiac surgery
We recommend the administration of tranexamic acid 
to reduce perioperative blood loss and/or transfusion 
rate. Grade 1A.
Compared with placebo, TXA reduced transfusion 
rate and the risk of reoperation for persistent or 
recurrent bleeding in patients undergoing cardiac 
surgery with CPB116. In myocardial revascularisation 
surgery without CPB, TXA administration reduced 
the risk of receiving ABT117. Topical administration 
of TXA reduced postoperative bleeding, but not ABT 
requirements118.    
We recommend the administration of ɛ-aminocaproic 
acid for reducing perioperative blood loss and/or 
transfusion rate. Grade 1B.
In cardiac surgery with CPB, EACA administration 
reduced ABT requirements and the rate of re-exploration 
for bleeding116. On the other hand, in the BART study, 
EACA and TXA showed similar efficacy in reducing 
bleeding and ABT requirements119, and the blood-saving 
effects of both agents were observed even in patients 
treated with aspirin120.
4.3.3. Hepatic surgery
We recommend the administration of tranexamic acid 
to reduce perioperative blood loss and/or transfusion 
rate. Grade 1B.
In liver transplantation, the administration of high 
doses of TXA reduced ABT requirements, while the 
continuous infusion of low doses of TXA reduced 
fibrinolysis but not ABT requirements121. A RCT of 
214 patients undergoing liver resection showed that 
TXA administration reduced intraoperative bleeding 
and surgery time and abolished the need for ABT122.
4.3.4. Miscellaneous surgery
We suggest the administration of tranexamic acid to 
reduce perioperative blood loss and/or transfusion rate 
in patients undergoing gynaecological or urological 
surgery. Grade 2A.
In elective Caesarean section, one RCT including 
660 patients showed that TXA administration reduced 
the volume of blood loss, the percentage of women with 
a blood loss of more than 1,000 mL and the need for 
uterotonics123. In radical retropubic prostatectomy, one RCT 
involving 200 patients showed that administration of TXA 
reduced intraoperative blood loss and transfusion rate124.
4.3.5. Trauma patients with severe bleeding
We recommend the administration of tranexamic 
acid to reduce blood loss and/or mortality rate. Grade 
1B.
The results from the CRASH-2 study, a RCT 
involving more than 20,000 patients from 274 
hospitals in 40 countries, showed that administration 
of TXA within 8 hours of injury significantly reduced 
mortality from all causes (14.5% vs 16%), including 
mortality due to bleeding (4.9% vs 5.7%)125. More 
recently, a retrospective study of 896 military patients 
wounded in combat showed an association between the 
administration of TXA and lower rates of coagulopathy 
and mortality, especially among those who needed 
massive transfusion126.
4.3.6. Gastrointestinal haemorrhage
We suggest the administration of tranexamic acid 
to reduce blood loss and improving clinical outcome. 
Grade 2A.
In a meta-analysis of RCTs, including 1,267 patients 
with gastrointestinal haemorrhage due to ulcer or 
mucosal erosion, the administration of TXA reduced 
by 20-30% the rate of re-bleeding, avoided surgery in 
40% of patients, and decreased mortality rate by 40%. 
Despite these good results, TXA is not frequently used 
in gastrointestinal haemorrhage, mostly because of the 
efficacy of other compounds and the use of endoscopic 
procedures to arrest bleeding127.
4.3.7. Dosage
The doses of TXA used most frequently in the studies 
reviewed were: 
- Total hip or knee arthroplasty: an initial dose of 
10-15 mg/kg before surgery, followed or not by 
infusion of 1 mg/kg/h for 4-6 h or the repetition of 
the initial dose in the postoperative period. 
- Spinal surgery: an initial dose of 20-100 mg/kg, 
followed by an infusion of 10 mg/kg/h for 4-6 h.
- Cardiac surgery with CPB and liver transplantation: 
an initial dose of 30 mg/kg followed by an infusion 
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of 16 mg/kg/h until the end of the surgery (plus 2 
mg/kg in the CPB circuit).
- Cardiac surgery without CPB: an initial dose of 1 g, 
followed by an infusion of 200-400 mg/h until the 
end of the surgery. 
- Topical use in cardiac and orthopaedic surgery: 1-3 g. 
- Caesarean section: 1 g preoperatively. 
- Prostatectomy: an initial dose of 500 mg/20 min 
followed by an infusion of 250 mg/h until the end 
of the surgery. 
- Bleeding trauma: 1 g in 10 min within the first 8 hours 
after the trauma, followed by an infusion of 1 g in 8 
hours. 
- Gastrointestinal bleeding: 3-6 g/day IV for 3 days. 
Epsilon-amino-caproic acid seems to be of use only 
in cardiac surgery. A starting dose of 10 g followed by 
an infusion of 2 g/h until the end of surgery was used 
in the BART study (no medication was added to the 
CPB circuit)119.
4.3.8. Safety
The studies analysed did not show that synthetic 
antifibrinolytic agents increased the risks of either 
thromboembolic events (including myocardial infarction, 
stroke, venous thrombosis or pulmonary embolism) or 
mortality. However, an increased rate of postoperative 
seizures has been described in patients undergoing 
cardiac surgery who received high doses of TXA, 
especially those with a history of renal dysfunction128,129.
4.3.9. Summary
TXA and EACA are used in a wide range of 
haemorrhagic conditions and in patients at haemorrhagic 
risk. Their effectiveness in reducing blood loss, 
transfusion requirements and number of re-operations 
for bleeding has been demonstrated in surgery and 
trauma. With the exception of cardiac surgery, TXA 
seems to be more effective than EACA. In these 
clinical settings, randomised studies have not shown 
that synthetic antifibrinolytic agents increase the risks 
of thrombotic events or mortality. However, the use of 
synthetic antifibrinolytic agents in orthopaedic surgery 
is an "off-label" indication, and more safety studies are 
needed before drawing a definitive recommendation in 
this setting. 
4.4. Desmopressin
Desmopressin (DDAVP) is a synthetic vasopressin 
analogue which has some haemostatic effects deriving 
from its ability to increase platelet adhesion (by 
increasing the expression of platelet receptor GPIb) and 
plasma levels of factor VIII and von Willebrand factor 
(by increasing their release from hepatic sinusoidal 
endothelial cells). 
4.4.1. Patients undergoing elective surgery
We do not recommend the use of desmopressin to 
reduce blood loss and/or transfusion rate in elective 
surgical procedures in patients without von Willebrand's 
disease Grade 1A.
A meta-analysis performed on 18 studies with a total 
of 1,295 patients showed that administration of DDAVP 
did not reduce blood loss or transfusion rate130.
4.4.2. Dosage
A 3- to 4-fold increase in plasma levels of von 
Willebrand factor occurs within 30-60 minutes of the 
administration of 0.3 mg/kg DDVAP. This increment 
is independent of the route of administration and lasts 
for 5-10 hours. However, it must be borne in mind that 
DDVAP produces tachyphylaxis (i.e., repeated doses 
cause depletion of endothelial reserves of von Willebrand 
factor), leading to loss of effectiveness in 24 h1.
4.4.3. Safety
Patients receiving DDVAP did not experience an 
increase in the rate of postoperative nonfatal acute 
myocardial infarction, reoperation for bleeding or 
mortality when compared with those from a control group. 
4.4.4. Summary
Desmopressin administration increases platelet 
adhesiveness and plasma levels of factor VIII and 
von Willebrand factor. This compound is useful in 
the prevention and control of haemorrhage in patients 
suffering from mild or moderate von Willebrand's 
disease. However, there is not convincing evidence 
supporting a role for DDAVP in reducing perioperative 
blood loss or transfusion rate in patients without 
inherited haemorrhagic disorders, and its use in these 
populations of patients is not recommended.
4.5. Recombinant activated factor VII 
Recombinant activated factor VII is a biological 
agent with procoagulant properties, which was 
developed initially for the treatment of bleeding in 
haemophilic patients with inhibitors against factors VIII 
and IX, and in patients with acquired haemophilia. In 
Europe, the authorisation of its use has been extended 
to patients with selective deficiency of factor VII and 
Glanzmann's thrombasthenia.
4.5.1. Patients with intractable bleeding refractory to 
conventional haemostatic interventions
We suggest the use of activated factor VII for the 
treatment of severe refractory haemorrhage. Grade 2C.
Recombinant activated factor VII has been used in 
patients with critical bleeding in the context of different 
surgical and non-surgical procedures, such as trauma, 
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cardiac and hepatic surgery and postpartum haemorrhage. 
Although it exerted a variable effect on morbidity and 
transfusion requirements, a beneficial effect on mortality 
has not been observed and a clear indication for it use is 
lacking99,131-133. A study in patients with trauma and active 
bleeding was prematurely discontinued when similar rates 
of mortality between rFVIIa-treated and placebo groups 
were recorded (12% versus 11%)134. Similarly, no benefit 
of rFVIIa administration was observed in patients with 
intracranial haemorrhage or haemorrhage secondary to 
oesophageal varices135,136.
A systematic review evaluating the use of rFVIIa in 
five different clinical settings (intracranial haemorrhage, 
cardiac surgery, trauma, liver transplantation and 
prostatectomy) concluded that there was no evidence of 
a reduction of mortality rates with rFVIIa, whereas the 
clotting factor increased the risk of thromboembolism 
in some clinical settings137.
4.5.2. Dosage
Although rFVIIa doses varied between studies 
(9-100 g/kg), for patients with refractory critical 
haemorrhage requiring massive transfusion, doses of 
90 g/kg seem to be reasonable.
4.5.3. Safety
Important rFVIIa-associated side effects, especially 
thromboembolic complications, have been reported138,139. 
In a recent meta-analysis of 35 studies of over 4,000 
randomised subjects the incidence of arterial thrombotic 
events (5.5%) and coronary events (2.9%) among 
patients receiving rFVIIa was significantly higher than 
that among those receiving placebo. These differences 
were more pronounced in patients older than 65 years 
(9% versus 4.1%, P =0.02)139.
4.5.4. Summary
There is insufficient good quality evidence to 
support the indiscriminate use of rFVIIa in severe 
haemorrhage to halt bleeding or reduce transfusion 
requirements. The design of most available studies 
is complex and the number of patients too small to 
detect a clear benefit. Exceptionally, the use of this 
clotting factor may be considered in patients with 
life-threatening haemorrhage after implementing 
conventional haemostatic measures. Given the paucity 
of evidence and the poor risk-to-benefit balance, 
administration of rFVIIa should only be considered for 
intractable bleeding of medical or surgical aetiology. 
Recombinant activated factor VII should, therefore, 
be administered on an individual basis, according to 
the clinical scenario, the characteristics of the patient 
and the medical judgement of the risk-to-benefit ratio 
in each case.
Pharmacological alternatives to stimulate 
erythropoiesis
4.6. Iron
It is well known that the preoperative haemoglobin 
level is the main independent risk factor for receiving 
ABT. Normal erythropoiesis needs a healthy bone 
marrow with an adequate supply of various nutrients 
(iron, vitamins C, B1, B6, B12 and folic acid), and 
hormones (erythropoietin, thyroid hormones and 
steroids). In the absence of information on other 
haematinics, only the possible benefit of oral and 
IV iron administration to reduce transfusion rate 
will be discussed. The intramuscular route for iron 
administration is not recommended.
4.6.1. Preoperative oral iron therapy 
We suggest preoperative administration of oral iron 
to improve preoperative haemoglobin levels and/or 
reduce transfusion rate. Grade 2B.
Colon cancer surgery. In anaemic patients, the 
administration of ferrous salts, starting 14 to 30 days 
prior surgery, improved the level of haemoglobin and 
decreased transfusion rate140,141. 
Orthopaedic surgery. In patients scheduled for total 
knee or hip arthroplasty, the administration of oral iron, 
together with a restrictive transfusion protocol, improved 
haemoglobin levels, reduced transfusion rates and, in 
some cases, the length of hospital stay142,143.
4.6.2. Postoperative oral iron therapy
We do not recommend postoperative administration 
of oral iron to improve postoperative haemoglobin levels 
and/or reduce transfusion rate. Grade 1B.
Surgical patients. The results of several RCT of 
patients undergoing surgery for total hip arthroplasty, 
total knee arthroplasty, hip fracture repair or myocardial 
revascularisation showed that administration of oral iron 
did not hasten the correction of postoperative anaemia 
or reduce the transfusion rate, but was associated with 
a high rate of adverse effects144-146. 
Critically ill patients. The administration of oral iron 
decreased the transfusion rate, but only when previously 
transfused patients were included in data analysis147.
4.6.3. Preoperative intravenous iron therapy
We suggest preoperative administration of 
intravenous iron to improve preoperative haemoglobin 
levels and/or reduce transfusion rate. Grade 2B.
Surgical patients. In anaemic patients scheduled for 
orthopaedic, gynaecological or digestive tract surgery, 
preoperative administration of IV iron sucrose or 
ferric carboxymaltose corrected anaemia and reduced 
the transfusion rate148. In a study of 437 patients with 
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colorectal cancer, early multidisciplinary assessment 
and treatment of anaemia (74% with IV iron) improved 
preoperative haemoglobin levels and reduced the 
transfusion rate149. However, in a RCT of colon cancer 
patients, preoperative IV iron sucrose did not increase 
haemoglobin levels, although there was a trend to lower 
transfusion rates150.
4.6.4. Perioperative intravenous iron therapy 
We suggest perioperative administration of 
intravenous iron to surgical patients expected to 
develop severe postoperative anaemia in order to reduce 
transfusion rate. Grade 2B.
Orthopaedic surgery. In hip fracture patients, 
perioperative administration of IV iron plus restrictive 
transfusion therapy decreased the transfusion rate and 
postoperative morbidity, especially in non-anaemic 
patients and in those with subcapital hip fracture151-153. 
In anaemic hip fracture patients, administration of IV 
iron plus rHuEPO (1×40,000 IU) was more effective 
than IV iron alone at reducing the transfusion rate154,155. 
Similarly, in patients undergoing total knee arthroplasty, 
the administration of IV iron (plus 1×40,000 IU rHuEPO 
if Hb <130 g/L) significantly reduced the transfusion 
rate156.
4.6.5. Postoperative intravenous iron therapy
We suggest postoperative administration of 
intravenous iron to improve haemoglobin levels and/or 
reduce transfusion rate. Grade 2C.
Cardiac surgery. The administration of IV iron, with 
or without rHuEPO, neither improved haemoglobin 
levels nor reduced the transfusion rate, although it did 
increase ferritin levels and reticulocyte counts157.
Orthopaedic surgery. In lower limb arthroplasty158 and 
correction of scoliosis159, postoperative IV iron improved 
haemoglobin levels and/or reduced transfusion rates. 
Gynaecological surgery. Postoperative IV iron 
significantly improved haemoglobin levels160,161. 
4.6.6. Intravenous iron therapy for moderate-to-severe 
post-partum anaemia
We recommend intravenous iron administration to 
correct anaemia and reduce transfusion rate. Grade 1B.
Administration of IV iron sucrose162,163 or ferric 
carboxymaltose164,165 improved anaemia, ferritin levels 
and quality of life, and reduced transfusion rate.
4.6.7. Intravenous iron therapy in inflammatory bowel 
disease
We recommend intravenous iron administration 
to correct iron deficiency and anaemia and reduce 
transfusion rate. Grade 1B.
Compared with oral iron, IV iron sucrose166,167 
and ferric carboxymaltose168 were more effective at 
correcting the anaemia and replenishing iron deposits, 
and had a lower rate of side effects. Treatment with IV 
ferric carboxymaltose was shown to be superior to that 
with IV iron sucrose169.
4.6.8. Intravenous iron therapy in cancer-associated 
anaemia 
We suggest the administration of intravenous iron, 
without erythropoiesis- stimulating agents, to prevent 
chemotherapy/radiotherapy-induced decreases in 
haemoglobin and to reduce transfusion rate. Grade 2B.
Data from two studies involving 134 patients with 
gynaecological cancer receiving adjuvant chemotherapy 
and/or radiotherapy showed that IV iron administration 
improved haemoglobin levels and reduced transfusion 
rate170,171. 
We recommend the administration of intravenous 
iron, as an adjuvant to erythropoiesis-stimulating 
agents, to correct chemotherapy-induced anaemia and 
reduce transfusion rate. Grade 1A.
A meta-analysis172 documented that the administration 
of IV iron plus erythropoiesis-stimulating agents 
corrected anaemia and improved transfusion rate, 
without increasing the rate of adverse effects. In 
addition, because IV iron allows doses of erythropoiesis-
stimulating agents to be reduced, IV iron adjuvant 
therapy can be cost-effective173.
4.6.9. Dosage
Oral iron. There is huge variability in the content of 
elemental iron among different oral iron formulations. 
For the treatment of preoperative anaemia, we 
recommend a dose of 100 mg of elemental iron/day 
for 2-6 weeks, depending on the time available before 
surgery.  One RCT in critically ill patients used ferrous 
sulphate 325 mg/day (65 mg elemental iron)147.
IV iron. The amount of IV iron required to replenish 
total iron deficiency can be estimated using Ganzoni's 
formula: 
Total iron deficiency = 
[target Hb ‒ current Hb] × weight × 0.24 + 500. 
In addition, 200 mg IV iron per 500 mL of blood 
loss should be administered. The administration 
schedule will depend on the IV iron formulation 
used: 
- Iron sucrose: up to 3 mg/kg/session, maximum 200 
mg/session, maximum 600 mg/week. 
- Ferric carboxymaltose: up to 20 mg/kg/session, 
maximum 1,000 mg/session, maximum 1,000 mg/week. 
- Iron isomaltoside 1000: up to 20 mg/kg/session, 
maximum 2,000 mg/session. 
- Low molecular weight iron dextran: up to 20 mg/kg/
session.
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4.6.10. Safety
Although no serious IV iron-related adverse effects 
have been described, the number of surgical patients 
enrolled in the studies analysed is insufficient to 
draw definitive conclusions. The frequency of severe 
adverse effects with non-dextran IV iron formulations 
is extremely low174 and significantly lower than the 
frequency with ABT175. A small proportion of patients 
treated with iron dextran have had anaphylactic 
reactions and, to a greater extent,  anaphylactoid 
reactions. With regards to the risk of infection, a 
study of 32,566 haemodialysis patients showed no 
correlation between the administration of IV iron and 
increased rates of infection or mortality176. In contrast, 
in patients undergoing major surgery, low preoperative 
ferritin levels were associated with increased rates of 
postoperative infections177,178. However, administration 
of IV iron should be avoided in patients with pre-
treatment ferritin values >300-500 ng/mL and transferrin 
saturation >50%. Moreover, despite the absence of 
definitive clinical data, it seems reasonable to avoid 
IV iron administration in the setting of acute infection. 
4.6.11. Summary
Iron deficiency and iron-deficiency anaemia are 
frequent among medical, surgical and critically ill 
patients. Iron supplementation may, therefore, contribute 
significantly to the correction of anaemia and/or reduction 
of the transfusion rate. Whenever there is enough 
time and no contraindications, iron supplementation 
should be given in the oral formulation (e.g., ferrous 
sulphate), because of its low cost, easy administration, 
and acceptable tolerance. However, if there is poor 
absorption or poor tolerance, or an accelerated response 
to treatment is required, it would be fully justified to use 
IV iron, which allows a more rapid and complete bone 
marrow response and iron store replenishment. With 
the exception of high molecular weight iron dextran, IV 
iron formulations have a favourable benefit-risk profile 
in the treatment of iron-deficiency anaemia in different 
acute and chronic conditions. 
4.7. Recombinant human erythropoietin
Recombinant human erythropoietin, obtained by 
genetic engineering, was initially authorised to treat the 
anaemia associated with chronic renal failure. After IV 
or subcutaneous administration, it mimics the effects of 
endogenous erythropoietin, stimulating erythropoiesis, 
inhibiting apoptosis of erythroid precursors and promoting 
their proliferation and maturation to erythrocytes. Its 
indications have now been expanded to the correction 
of anaemia and avoidance of ABT in patients receiving 
chemotherapy for non-myeloid malignancies, as well as 
in patients included in a PABD programme or scheduled 
for elective orthopaedic surgery.
4.7.1. Elective orthopaedic surgery
We recommend preoperative administration of 
recombinant human erythropoietin to reduce transfusion 
rate in patients with moderate anaemia (haemoglobin 
between 100 and 130 g/L) who are expected to have 
moderate blood losses. Grade 1A. 
In a meta-analysis on three randomised trials 
involving 684 patients with moderate anaemia who 
were scheduled for lower limb prosthetic surgery, 
preoperative administration of rHuEPO significantly 
reduced the risk of receiving ABT179. Subsequently, 
two RCT (896 patients)180,181 and a case-control study 
(770 patients)182 documented a similar reduction in 
transfusion rate.
4.7.2. Other major surgical procedures 
We suggest the administration of recombinant human 
erythropoietin to reduce transfusion rate in anaemic 
patients undergoing major surgery. Grade 2A.
Cardiac surgery. In a meta-analysis of RCT, 
preoperative administration of rHuEPO reduced the 
transfusion rate in patients undergoing cardiac surgery 
with CPB183. More recently, three RCT demonstrated 
the utility of a single dose of rHuEPO in the immediate 
preoperative period to reduce transfusion requirements 
in procedures with or without CPB184-186. However, there 
is no evidence that postoperative rHuEPO hastens the 
recovery from postoperative anaemia157. 
Gastrointestinal cancer. Several RCT, mainly 
in patients with colorectal cancer, have shown an 
increase in haemoglobin levels and a decrease in ABT 
requirements, but rHuEPO doses and treatment duration 
varied between studies. However, it could be verified 
that IV iron improved the efficacy of rHuEPO187-189.
4.7.3. Critically ill patients
We do not recommend the use of recombinant 
human erythropoietin to treat anaemia and reduce the 
transfusion rate in patients who do not have a previous 
indication, with the possible exception of trauma patients, 
particularly those with severe traumatic brain injury. 
Grade 1A.
It has been documented that, when a restrictive 
transfusion protocol was implemented, administration of 
rHuEPO decreased transfusion requirements discretely, 
but without reducing mortality190. In addition, a net 
increase in haemoglobin was only observed in one 
study in which adjuvant therapy with IV iron was 
administered191. However, for critically ill patients who 
were younger (<55 years) or presented with initially 
less severe illness (APACHE score <20) or with trauma 
as their admission diagnosis, rHuEPO administration 
improved survival rates192. Similar findings were 
observed in a population of patients with severe 
traumatic brain injury193.
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4.7.4. Dosage
Orthopaedic surgery. Two different protocols of 
rHuEPO administration have been adopted: 4 doses 
of 600 IU/Kg/week subcutaneously, beginning 3 
weeks before surgery, or 15 doses of 300 IU/Kg/day, 
beginning 10 days prior to surgery and continuing 
4 days after it. Similar protocols have been used 
in cardiac and oncological surgery. Although the 
effectiveness of these two protocols has been fully 
proven, the minimum effective dose of rHuEPO to 
reduce the transfusion rate in these patients is unknown, 
as similar results have been obtained using lower doses 
and shorter periods of administration, especially with 
adjuvant IV iron therapy156,180,183-185,194,195.
4.7.5. Safety 
Various government agencies (US Food and Drug 
Administration, European Medicines Agency, and the 
Spanish Agency of Medicines and Sanitary Products) 
have issued alerts on the association between the use 
of rHuEPO and an increased risk of thromboembolic 
events and mortality in patients receiving long-
term treatment for anaemia associated with chronic 
renal failure or cancer chemotherapy, as well as in 
patients undergoing orthopaedic surgery without 
thromboembolic prophylaxis196. The RCT analysed 
documented that administration of rHuEPO in surgical 
and critically ill patients did not result in significantly 
higher rates of deep venous thrombosis or other 
clinically relevant thrombotic events when compared 
with a control group, provided that patients received 
pharmacological thromboembolic prophylaxis. 
However, it should be remembered that, except for 
patients scheduled for elective orthopaedic procedures 
or included in a PABD programme, the use of rHuEPO 
in surgical patients is "off-label". The available data 
do, therefore, suggest that it would be necessary to 
adjust the rHuEPO dose (administering adjuvant iron, 
preferably IV), as well as to pay special attention 
to thromboembolic prophylaxis (administering 
anti-thrombotic and, perhaps, platelet antiaggregant 
drugs)191,197,198.
4.7.6. Summary
The administration of rHuEPO is indicated to 
correct anaemia and reduce the transfusion rate in 
patients undergoing elective orthopaedic surgery, and 
to facilitate the implementation of PABD programmes 
requiring three or more units of blood. The efficacy 
of rHuEPO in reducing the rate of ABT is maximal in 
patients with preoperative haemoglobin levels between 
100 and 130 g/L and the product does not apparently 
increase the incidence of thrombotic complications. 
However, it must be borne in mind that these are low 
incidence adverse effects, and that the majority of 
studies with rHuEPO have been performed in patients 
without cardiovascular disease. It would, therefore, 
be advisable to adjust rHuEPO dose individually, 
ensure iron supply to the bone marrow and provide 
adequate thomboembolic prophylaxis. In addition, 
rHuEPO could be administered to treat anaemia in non-
orthopaedic surgical patients ("off-label" use), but it is 
not recommended for critically ill patients who do not 
have a prior indication for this drug, with the possible 
exception of trauma patients, particularly those with 
severe traumatic brain injury. 
Pharmacological alternatives  to improve 
oxygen transport
4.8 Crystalloids and colloids solutions
The correction of haemorrhage-associated 
hypovolaemia, administering IV crystalloid and/or 
colloid solutions, is a priority measure and, in itself, 
the first AABT to be considered in the event of any 
acute or subacute haemorrhage, as hypovolaemia is 
tolerated less well than anaemia. Isotonic 0.9% saline, 
Ringer's solution and other balanced salt solutions, such 
as Hartmann's solution (Ringer lactate), are among the 
most commonly used crystalloid solutions. They are 
inexpensive, do not alter haemostasis or renal function, 
and there is large accumulated experience with their 
use. Usually, only 25% of infused crystalloid volume 
is retained within the intravascular compartment. 
Hypertonic crystalloid solutions (1.8-7.2% NaCl) 
would have the theoretical advantages of a more rapid 
correction of hypovolaemia and reduction of cerebral 
oedema. However, there are no conclusive evidence 
of their efficacy and they may lead to hypernatremia. 
The most commonly used colloids are hydroxyethyl 
starch (HES), gelatine and human albumin solutions. 
Infusion of 5% albumin produces a plasma expansion 
equal to 75% of the volume infused. Gelatines, given 
their low molecular weight, have a short intravascular 
half life (2-3 hours) and their plasma expansion capacity 
is limited (70-80%). The 6% HES solutions have a 
longer intravascular half-life (6-8 hours) and larger 
plasma expansion capacity (80-120%), and are the most 
widely used colloids for volume expansion nowadays. 
Nevertheless, the discussion regarding selection of 
crystalloids or colloids for fluid resuscitation is as old 
as it is controversial199.
4.8.1. Patients with mild or moderate blood loss 
We recommend initial volume replacement with 
crystalloids or colloids to decrease the transfusion rate. 
Grade 1C.
Patients with mild or moderate haemorrhage (<30% 
of volaemia or <1,300 mL), without data on additional 
bleeding, can be managed with a crystalloid200,201. 
Adequate replenishment of the circulating volume and, 
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therefore, of the cardiac output, allows the maintenance 
of oxygen supply to tissues. Colloids may be reserved 
for patients who are haemodynamically unstable despite 
the infusion of crystalloids202,203.
4.8.2. Patients with severe blood loss 
We recommend initial volume replacement with 
crystalloids or colloids to decrease the transfusion rate. 
Grade 1C.
Patients with severe haemorrhage (30-40% of 
volaemia) can be initially managed with crystalloids200,201. 
It has been recommended to infuse small volumes of 
Ringer lactate, containing only the lactate L isomer, 
to maintain a systolic blood pressure of 80-90 mmHg 
(controlled or permissive hypotension)204. However, 
it seems justified to add colloids or vasoactive drugs, 
after initial resuscitation with moderate amounts of 
crystalloids. Once volaemia is restored, the need for 
ABT should be assessed on the basis of laboratory tests 
and estimated blood losses. A pooled analysis of RCT 
comparing various HES solutions in major surgery 
concluded that the administration of HES 130/0.4 may 
significantly reduce transfusion needs205.
4.8.3. Patients with critical bleeding 
We suggest initial fluid resuscitation with crystalloids 
or colloids, followed by transfusion of blood components 
and plasma derivatives, to decrease the transfusion rate. 
Grade 2B.
Immediate transfusion of blood products is 
recommended for patients with critical bleeding 
(>40% of volaemia), who do not respond to the 
initial infusion of 2 litres of fluids, have severe 
bleeding with haemodynamic instability or a 
blood loss ≥50 mL/minute206. Patients presenting 
with coagulopathy, acidosis and hypothermia have 
significantly worse outcome64. Classically, it was 
thought that the coagulopathy had a delayed onset and 
was due to bleeding-associated loss of coagulation 
factors, which were diluted further by the infusion of 
large amount of fluids. This justified the transfusion 
of blood products with low ratios of PRBC:FFP (6:1) 
and  PRBC:platelet concentrate (10:1).
However, recent studies have documented the 
very early onset of coagulopathy, which is present 
upon admission in up to a third of the patients, before 
fluid resuscitation64. It has been suggested that early 
administration of blood products in a 1:1:1 ratio (i.e., the 
same amounts of PRBC, FFP and platelet concentrate; 
the so-called "massive transfusion protocol"), rather 
than large amounts of fluids, increases survival64,83. 
However, it should be remembered that this practice 
is based on retrospective analysis, subject to a number 
of limitations and biases. Thus, some observational 
studies have demonstrated an association between 
early initiation of a massive transfusion protocol 
and improved clinical outcome, including decreased 
transfusion rates and increased survival64,83,207, although 
others have not84,208,209. Secondly, the design of the 
massive transfusion protocol for traumatic bleeding 
was based on data from the military context, which is 
often very different from the civilian context. Finally, 
it has not been conclusively demonstrated that the 
massive transfusion protocol decreases morbidity or 
improves survival in civilian patients with haemorrhagic 
trauma84,208,210,211. In a recent systematic review on 
this topic, the authors concluded that there is not 
sufficient evidence to indicate the use of the 1:1:1 
massive transfusion protocol in these populations of 
patients210. Similarly, the European Guidelines on 
Massive Transfusion99 and recent updates of clinical 
practice guidelines84,208,210,211 do not provide specific 
recommendations on the 1:1:1 massive transfusion 
protocol. Therefore, until new evidence is available, 
the traditional approach, based on volume replacement, 
monitoring of haemostasis and transfusion of the 
appropriate blood products, can be considered valid for 
the vast majority of bleeding patients.
4.8.4. Dosage
Crystalloids. An initial dose of 3 mL of crystalloids 
(preferably Ringer lactate) per mL of blood loss, at an 
infusion rate of 60-80 mL/kg/hour, while achieving 
bleeding control, is recommended. The objective 
should be to maintain a systolic blood pressure of 
80-90 mmHg (permissive hypotension)204. Patients 
with traumatic brain injury may require the infusion 
of larger amounts of fluid to maintain systolic blood 
pressure. Hypertonic saline solutions carry the potential 
risk of hypernatraemia, and only a single dose can be 
administered. The dose of the 7.2% NaCl solution, with 
or without HES, is 4 mL/kg, although this treatment is 
not widely used.  
Colloids. An initial dose of 1 mL of colloids per mL 
of blood loss is recommended. The maximal dose of HES 
is 20 mL/kg/day for HES 200/0.5 and 50 mL/kg/day for 
HES 130/0.4.  As gelatines do not accumulate in the 
body, a maximal daily dose has not been described, but 
it is recommended that the dose of 20 mL/kg/day is not 
exceeded200,204.
4.8.5. Safety
The infusion of large amounts of crystalloids 
(generally saline isotonic solution) is associated 
with an increased incidence of nausea, vomiting, 
generalised oedema, pulmonary dysfunction and 
hyperchloraemic metabolic acidosis204. Under normal 
conditions, the lactate of Ringer's lactate is quickly 
metabolised to bicarbonate, but some clinical and 
experimental observations indicate reduced lactate 
All rights reserved - For personal use only 
No other uses without permission
© 
SIM
TI 
Se
rvi
zi 
Srl
602
Leal-Noval SR et al
Blood Transfus 2013; 11: 585-610  DOI 10.2450/2013.0029-13
clearance in haemorrhagic shock, probably due to 
poor liver perfusion, leading to metabolic acidosis. 
Under ideal conditions, 25% of infused crystalloid 
volume remains within the vascular compartment, 
whereas the remaining 75% leaks into the extravascular 
compartment. Increased capillary permeability may 
reduce intravascular crystalloid retention, resulting in 
an increase of interstitial oedema.
Adverse effects of colloids include anaphylactoid 
reactions, pruritus, coagulopathy and haemorrhagic 
events, with varied incidences depending on the type of 
colloid. While gelatines are more frequently associated 
with anaphylactoid reactions, HES solutions are linked 
to itching and coagulopathy. High molecular weight 
HES may worsen kidney function in patients with 
pre-existing kidney disease, especially those with 
sepsis. Although HES solutions may alter the results 
of tests of haemostasis and decrease clot firmness, the 
administration of low molecular weight HES rarely 
results in clinically relevant coagulopathy leading to 
bleeding complications. The administration of HES 
might produce a dose-dependent reduction of factor 
VII activity, mild platelet dysfunction, and prolonged 
activated partial thromboplastin time. Most of these 
changes have a dilutional aetiology, and may lead to 
increased blood loss, especially in patients undergoing 
cardiac surgery. Given its lower molecular weight 
and degree of substitution, pentastarch causes less 
haemostatic derangements than hetastarch. A recent 
Cochrane Database review of 63 RCT concluded that 
there are no data demonstrating that resuscitation 
with colloids, rather than with crystalloids, reduces 
mortality risk in patients with trauma, burns or 
surgery212. In addition, septic patients resuscitated 
with colloids, rather than crystalloids, had higher rates 
of mortality and renal failure213. In another study of 
patients admitted to an Intensive Care Unit, there was 
no significant difference in 90-day mortality between 
patients resuscitated with 6% HES (130/0.4) or saline. 
However, more patients who received resuscitation 
with HES were treated with renal-replacement 
therapy214.
4.8.6. Summary
Crystalloid solutions are inexpensive, do not alter 
haemostasis or produce renal damage, and there is large 
experience with their use. Their main disadvantage in 
that only 25% of infused volume is retained within the 
intravascular compartment. Isotonic saline is the most 
widely and safely used crystalloid solution. The available 
evidence indicates that crystalloids are the solutions of 
choice for the initial treatment of hypovolaemic acute 
anaemia due to moderate to severe bleeding. Another 
recommended management for severe bleeding is the 
infusion of small volumes of Ringer's lactate (60-80 
mL/kg/h) containing only the L isomer of lactate to 
maintain a systolic blood pressure of 80-90 mmHg 
(controlled or permissive hypotension). There is no 
evidence indicating that colloid solutions are superior 
to crystalloid solutions as an AABT. Colloids are used 
in the event of severe haemorrhage and haemodynamic 
instability, usually in association with crystalloids. 
Among colloids, HES are most widely used as an AABT, 
flowed by gelatines; the use of albumin as a plasma 
expander is not recommended.
4.9. Perfluorocarbon- and haemoglobin-based 
oxygen carriers
Perfluorocarbon-based oxygen carriers (PFCOC) 
are linear, cyclic or polycyclic hydrocarbon compounds 
in which hydrogen atoms have been replaced by 
fluorine atoms. They are characterised by having a high 
capacity to dissolve gases (O2, CO2, N and NO), and do 
not contain biological products. The amount of oxygen 
dissolved in perfluorocarbon emulsions is directly 
proportional to the patient's inspiratory O2 fraction.
Haemoglobin-based oxygen carriers (HBOC) 
are compounds derived from human, animal or 
recombinant haemoglobin and are free from cellular 
elements.
4.9.1. Administration of perfluorocarbon-based oxygen 
carriers to patients who are bleeding and/or 
require blood transfusion
We cannot make any recommendation regarding 
the use of perfluorocarbon-based oxygen carriers 
as an alternative to the transfusion of red blood cell 
concentrates. Grade 0.
Very few studies on the use of PFCOC as AABT 
have been published, and most of them have showed 
an increased rate of adverse effects215-217. No PFCOC is 
currently approved in the European Union for use as an 
AABT. Perftoran has been approved for use in Russia, 
Ukraine and Mexico. A RCT of 30 cardiac surgery 
patients conducted in Mexico concluded that the use 
of Perftoran did not result in a significant reduction 
of transfusion rate with respect to the rate in a control 
group218.
4.9.2. Administration of haemoglobin-based oxygen 
carriers to patients who are bleeding and/or 
require blood transfusion
We cannot make any recommendation regarding 
the use of haemoglobin-based oxygen carriers as 
an alternative to the transfusion of red blood cell 
concentrates. Grade 0.
A RCT of 688 orthopaedic surgery patients 
documented a decrease in ABT rate and an increase of 
All rights reserved - For personal use only 
No other uses without permission
© 
SIM
TI 
Se
rvi
zi 
Srl
603
Blood Transfus 2013; 11: 585-610  DOI 10.2450/2013.0029-13
Seville Document Update 2013
adverse events in the group that received Hemopure219. 
Similarly, although there are case-reports showing 
that PolyHeme administration may improve survival 
in extreme circumstances220, a recent clinical trial 
demonstrated that PolyHeme use did not provide any 
advantage in terms of survival or blood saving, and 
resulted in an even higher rate of adverse events221. A 
randomised, single-blind, dose escalation safety trial of 
Hemospan administered to orthopaedic surgery patients 
did not detect serious adverse events associated with the 
use of this HBOC222. No HBOC is currently approved 
as an AABT in the European Union.
4.9.3. Dosage
It is not possible to make recommendations regarding 
the doses of PFCOC or HBOC.
4.9.4. Safety
Initially, HBOC had very short intravascular half-
lives and caused significant adverse effects, including 
abdominal pain, hypertension and nephrotoxicity. 
Currently available products, which have been obtained 
using techniques of stabilising the haemoglobin 
molecule, have longer intravascular half-lives and 
lower rates of adverse effects, although notifications of 
HBOC-associated hypertension and acute renal failure 
still persist1,223. In general, PFCOC-related toxicity 
includes thrombocytopenia, complement activation and 
cytokine release, reticulo-endothelial system blockade, 
flu-like symptoms and central nervous system effects. 
4.9.5. Summary
Based on the available scientific evidence, the 
current role of artificial oxygen carriers as AABT is 
uncertain and limited in practice to specific situations 
in which human blood components were not available. 
However, should the ongoing research lines be fruitful, 
new oxygen carriers with improved safety profile could 
be available in the near future.
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Appendix A
Panel members (in alphabetical order):
Marisol Asuero
Misericordia Basora
Francisco José Bautista-Paloma 
Elvira Bisbe 
José Luís Bóveda 
Auxiliadora Castillo-Muñoz 
María José Colomina 
Enric Contreras
Carmen Fernández 
Enrique Fernández-Mondéjar
Carmen Ferrándiz 
Abelardo García de Lorenzo 
José Antonio García-Erce 
Carmen Gomar 
José Aurelio Gómez-Luque 
Mónica Izuel 
Víctor Jiménez-Yuste 
Santiago Ramón Leal-Noval
Eduardo López-Briz 
María Fernanda López-Fernández
Juan Vicente Llau
José Antonio Martín-Conde 
Bruno Montoro-Ronsano
Victoria Moral
Manuel Muñoz
Carmen Paniagua 
José Antonio Páramo
Manuel Quintana
José Antonio Romero-Garrido 
Juan Carlos Ruiz 
Ramón Salinas-Argente 
Calixto Sánchez
Pau Torrabadella 
Appendix B
Acronyms (in alphabetical order):
AABT Alternatives to allogeneic blood transfusion
ABT Allogeneic blood transfusion
ANH Acute normovolaemic haemodilution 
CPB  Cardiopulmonary bypass
DDAVP  Desmopressin 
EACA  Epsilon aminocaproic acid
FFP  Fresh-frozen plasma
GRADE Grades of Recommendation Assessment, Development 
 and Evaluation 
Hb  Haemoglobin 
HBOC  Haemoglobin-based oxygen carriers 
HES  Hydroxy ethyl-starches
INR  International Normalised Ratio
IV  Intravenous 
PABD  Preoperative autologous blood donation
PCC  Prothrombin complex concentrate
PFCOC  Perfluorocarbon-based oxygen carriers 
PRBC  Packed red blood cells 
PRCS Perioperative red cell salvage
RCT  Randomised controlled trials 
rFVIIa  Recombinant activated factor VII 
rHuEPO  Recombinant human erythropoietin 
SD  Seville Document, 2006 version
TACO  Transfusion-associated cardiovascular overload 
TEG  Thromboelastography
TRALI  Transfusion-related acute lung injury
TXA  Tranexamic acid
VKA  Vitamin K antagonists
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